Age years (n=119) | 58.7±14.4 |
18–29 | 4 (3.4, 0.8–6.7) |
30–39 | 11 (9.2, 5.0–14.3) |
40–49 | 13 (10.9, 6.7–15.1) |
50–59 | 36 (30.3, 22.7–38.7) |
60–69 | 27 (22.7, 16.0–28.6) |
70–79 | 18 (15.1, 10.1–21.0) |
≥80 | 10 (8.4, 5.0–12.6) |
Sex (n=119) | |
Female | 45 (37.8, 29.4–46.2) |
Male | 74 (62.2, 53.8–70.6) |
Ethnicity (n=119) | |
BAME (yes/no) | 83 (69.7, 61.3–78.2) |
White | 36 (30.3, 22.6–37.8) |
Black | 52 (43.7, 36.1–51.3) |
Asian | 18 (15.1, 10.1–20.2) |
Mixed race | 5 (4.2, 1.7–6.7) |
Other | 8 (6.7, 3.4–10.9) |
Index of multiple deprivation score (n=115) | 26.6±9.7 |
BMI kg·m−2 (n=118) | 30.0 (25.9–35.2) |
Underweight (<18.5) | 0 (0.0) |
Normal (18.5–24.9) | 22 (18.6, 12.7–24.6) |
Overweight (25.0–29.9) | 35 (29.7, 22.9–37.3) |
Obese (30.0–34.9) | 30 (25.4, 19.5–33.1) |
Severely obese (35.0–39.9) | 20 (16.9, 11.0–22.0) |
Morbidly obese (40.0–49.9) | 9 (7.6, 4.2–11.0) |
Super obese (≥50.0) | 2 (1.7, 0.0–4.2) |
Smoking status (n=110) | |
Never-smoker | 82 (74.5, 67.3–82.7) |
Ex-smoker | 25 (22.7, 16.4–28.2) |
Current smoker | 3 (2.7, 0.0–6.4) |
Comorbidities (n=119) | |
Charlson Comorbidity Index | 2 (1–4) |
Any cardiovascular disease | 63 (52.9, 44.5–61.8) |
Hypertension | 54 (45.4, 37.7–52.9) |
Hyperlipidaemia | 25 (21.0, 15.1–27.4) |
Ischaemic heart disease/heart failure | 8 (6.7, 3.4–10.9) |
Diabetes | 41 (34.5, 26.4–42.9) |
Immunosuppressed | 16 (13.4, 8.4–18.5) |
Obstructive lung disease | 13 (10.9, 6.7–16.0) |
Malignancy | 12 (10.1, 5.9–14.3) |
End-stage renal failure | 8 (6.7, 3.4–10.1) |
Thyroid disease | 7 (5.9, 2.5–9.2) |
Mental health condition | 6 (5.0, 2.5–7.6) |
Cerebrovascular disease | 5 (4.2, 1.7–6.7) |
Admission PaO2/FIO2 | 168.8 (105.9–272.3) |
PaO2/FIO2 severity (n=119) | |
>300 (normal) | 13 (14.6, 9.0–21.3) |
200–300 (mild) | 23 (25.8, 19.1–34.8) |
100–199 (moderate) | 32 (36.0, 28.1–44.9) |
<100 (severe) | 21 (23.6, 15.7–32.6) |
Maximum respiratory support (n=119) | |
FMO2 | 71 (59.7, 51.3–67.2) |
PAP | 14 (11.8, 6.9–16.8) |
IMV | 34 (28.6, 21.0–37.0) |
COVID-19 complications (n=119) | |
None during admission | 49 (41.2, 33.6–48.7) |
Venous thromboembolism | 27 (22.7, 16.8–29.4) |
Pulmonary embolism | 23 (19.3, 12.6–26.1) |
Deep vein thrombosis | 6 (5.0, 2.5–7.6) |
Acute kidney injury | 41 (34.5, 25.2–43.7) |
Deranged LFTs | 17 (14.3, 9.2–20.2) |
Delirium | 18 (15.1, 10.1–20.2) |
Hospital LOS days | 12 (8–23) |
LOS if admitted to ICU days | 30.8±16.3 |
LOS if not admitted to ICU days | 9 (7–14.5) |
ICU admission (n=119) | 41 (34.5, 26.9–42.9) |
ICU LOS days | 14.5 (7–27) |
Duration of IMV days | 20.5±14.0 |